Andrea Ciaranello1, Zhigang Lu, Samuel Ayaya, Elena Losina, Beverly Musick, Rachel Vreeman, Kenneth A Freedberg, Elaine J Abrams, Lisa Dillabaugh, Katie Doherty, John Ssali, Constantin T Yiannoutsos, Kara Wools-Kaloustian. 1. From the *Division of Infectious Diseases and Medical Practice Evaluation Center; †Division of General Medicine and Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA; ‡Department of Child Health and Paediatrics, Moi University School of Medicine, Eldoret, Kenya; §Department of Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA; ¶Department of Biostatistics, Indiana University; ‖Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN; **ICAP, Mailman School of Public Health, Columbia University and College of Physicians and Surgeons, Columbia University, NY; ††Family AIDS Care and Education Service (FACES) program, Kisumu, Kenya; ‡‡Department of Pediatrics, University of California, San Francisco, CA; §§Masaka Regional Referral Hospital, AHF-Uganda Cares Masaka, Uganda; and ¶¶Division of Infectious Disease, Indiana University School of Medicine, Indianapolis, IN.
Abstract
BACKGROUND: Few studies have reported CD4%- and age-stratified rates of World Health Organization Stage 3 (WHO3) events, World Health Organization Stage 4 (WHO4) events, tuberculosis (TB) and mortality in HIV-infected infants before initiation of antiretroviral therapy. METHODS: HIV-infected children enrolled before 1 year of age in the International Epidemiologic Databases to Evaluate AIDS East Africa region (October 1, 2002, to November, 2008) were included. We estimated incidence rates of earliest clinical event (WHO3, WHO4 and TB), before antiretroviral therapy initiation per local guidelines, stratified by current age (< or ≥6 months) and current CD4% (<15%, 15-24%, ≥25%). CD4%-stratified mortality rates were estimated separately for children who did not experience a clinical event ("background" mortality) and for children who experienced an event, including "acute" mortality (≤30 days post event) and "later" mortality (>30 days post event). RESULTS: Among 847 children (median enrollment age: 4.8 months; median pre-antiretroviral therapy follow up: 10.8 months; 603 (71%) with ≥1 CD4% recorded), event rates were comparable for those aged <6 and ≥6 months. Current CD4% was associated with risk of WHO4 events for children <6 months of age and with all evaluated events for children ≥6 months old (P < 0.05). "Background" mortality was 3.7-8.4/100 person-years (PY). "Acute" mortality (≤30 days post event) was 33.8/100 PY (after TB) and 41.1/100 PY (after WHO3 or WHO4). "Later" mortality (>30 days post event) ranged by CD4% from 4.7 to 29.1/100 PY. CONCLUSIONS: In treatment-naïve, HIV-infected infants, WHO3, WHO4 and TB events were common before and after 6 months of age and led to substantial increases in mortality. Early infant HIV diagnosis and treatment are critically important, regardless of CD4%.
BACKGROUND: Few studies have reported CD4%- and age-stratified rates of World Health Organization Stage 3 (WHO3) events, World Health Organization Stage 4 (WHO4) events, tuberculosis (TB) and mortality in HIV-infectedinfants before initiation of antiretroviral therapy. METHODS:HIV-infectedchildren enrolled before 1 year of age in the International Epidemiologic Databases to Evaluate AIDS East Africa region (October 1, 2002, to November, 2008) were included. We estimated incidence rates of earliest clinical event (WHO3, WHO4 and TB), before antiretroviral therapy initiation per local guidelines, stratified by current age (< or ≥6 months) and current CD4% (<15%, 15-24%, ≥25%). CD4%-stratified mortality rates were estimated separately for children who did not experience a clinical event ("background" mortality) and for children who experienced an event, including "acute" mortality (≤30 days post event) and "later" mortality (>30 days post event). RESULTS: Among 847 children (median enrollment age: 4.8 months; median pre-antiretroviral therapy follow up: 10.8 months; 603 (71%) with ≥1 CD4% recorded), event rates were comparable for those aged <6 and ≥6 months. Current CD4% was associated with risk of WHO4 events for children <6 months of age and with all evaluated events for children ≥6 months old (P < 0.05). "Background" mortality was 3.7-8.4/100 person-years (PY). "Acute" mortality (≤30 days post event) was 33.8/100 PY (after TB) and 41.1/100 PY (after WHO3 or WHO4). "Later" mortality (>30 days post event) ranged by CD4% from 4.7 to 29.1/100 PY. CONCLUSIONS: In treatment-naïve, HIV-infectedinfants, WHO3, WHO4 and TB events were common before and after 6 months of age and led to substantial increases in mortality. Early infant HIV diagnosis and treatment are critically important, regardless of CD4%.
Authors: T E Taha; S M Graham; N I Kumwenda; R L Broadhead; D R Hoover; D Markakis; L van Der Hoeven; G N Liomba; J D Chiphangwi; P G Miotti Journal: Pediatrics Date: 2000-12 Impact factor: 7.124
Authors: Theodore D Ruel; Michael J Boivin; Hannah E Boal; Paul Bangirana; Edwin Charlebois; Diane V Havlir; Philip J Rosenthal; Grant Dorsey; Jane Achan; Carolyne Akello; Moses R Kamya; Joseph K Wong Journal: Clin Infect Dis Date: 2012-02-04 Impact factor: 9.079
Authors: D Mbori-Ngacha; R Nduati; G John; M Reilly; B Richardson; A Mwatha; J Ndinya-Achola; J Bwayo; J Kreiss Journal: JAMA Date: 2001-11-21 Impact factor: 56.272
Authors: T E Taha; N I Kumwenda; D R Hoover; R J Biggar; R L Broadhead; S Cassol; L van der Hoven; D Markakis; G N Liomba; J D Chiphangwi; P G Miotti Journal: AIDS Date: 2000-03-10 Impact factor: 4.177
Authors: Andrea L Ciaranello; Ji-Eun Park; Lynn Ramirez-Avila; Kenneth A Freedberg; Rochelle P Walensky; Valeriane Leroy Journal: BMC Med Date: 2011-05-20 Impact factor: 8.775
Authors: Heather B Jaspan; Landon Myer; Shabir A Madhi; Avy Violari; Diana M Gibb; Wendy S Stevens; Els Dobbels; Mark F Cotton Journal: BMC Pediatr Date: 2011-11-21 Impact factor: 2.125
Authors: Christopher T Andersen; Christopher P Duggan; Karim Manji; George R Seage; Donna Spiegelman; Nandita Perumal; Nzovu Ulenga; Wafaie W Fawzi Journal: Int J Epidemiol Date: 2022-10-13 Impact factor: 9.685
Authors: Jordan A Francke; Martina Penazzato; Taige Hou; Elaine J Abrams; Rachel L MacLean; Landon Myer; Rochelle P Walensky; Valériane Leroy; Milton C Weinstein; Robert A Parker; Kenneth A Freedberg; Andrea Ciaranello Journal: J Infect Dis Date: 2016-08-17 Impact factor: 5.226
Authors: Reuben Granich; Somya Gupta; Bradley Hersh; Brian Williams; Julio Montaner; Benjamin Young; José M Zuniga Journal: PLoS One Date: 2015-07-06 Impact factor: 3.240
Authors: Andrea L Ciaranello; Kathleen Doherty; Martina Penazzato; Jane C Lindsey; Linda Harrison; Kathleen Kelly; Rochelle P Walensky; Shaffiq Essajee; Elena Losina; Lulu Muhe; Kara Wools-Kaloustian; Samuel Ayaya; Milton C Weinstein; Paul Palumbo; Kenneth A Freedberg Journal: AIDS Date: 2015-06-19 Impact factor: 4.177
Authors: Andrea L Ciaranello; Bethany L Morris; Rochelle P Walensky; Milton C Weinstein; Samuel Ayaya; Kathleen Doherty; Valeriane Leroy; Taige Hou; Sophie Desmonde; Zhigang Lu; Farzad Noubary; Kunjal Patel; Lynn Ramirez-Avila; Elena Losina; George R Seage; Kenneth A Freedberg Journal: PLoS One Date: 2013-12-13 Impact factor: 3.240
Authors: Andrea L Ciaranello; Landon Myer; Kathleen Kelly; Sarah Christensen; Kristen Daskilewicz; Katie Doherty; Linda-Gail Bekker; Taige Hou; Robin Wood; Jordan A Francke; Kara Wools-Kaloustian; Kenneth A Freedberg; Rochelle P Walensky Journal: PLoS One Date: 2015-03-10 Impact factor: 3.240